All In Biotech

Drug Trial Radar · NCT03131141

A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781

An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of 14C-BC-3781 Administered Via the Intravenous or Oral Routes to Healthy Male Subjects

Last checked: Nov 19, 2026Latest source record: Apr 3, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

10

Actual

Start

Jan 8, 2017

Primary completion

Oct 9, 2017

Study completion Mar 30, 2018

Sponsor

Lead sponsor
Nabriva Therapeutics AGIndustry
Sponsor type
Industry
Collaborators
Quotient Clinical
First posted
Apr 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 30 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-centre, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled BC-3781 administered via the intravenous or oral routes.

Conditions

  • Healthy

Interventions

  • BC-3781Drug

    Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Amount of radioactivity eliminated in urineTime frame: Day 1 pre-dose to Day 8 post-dose
  2. Amount of radioactivity eliminated in fecesTime frame: Day 1 pre-dose to Day 8 post-dose
  3. Amount of radioactivity eliminated in urine and fecesTime frame: Day 1 pre-dose to Day 8 post-dose
  4. Cumulative amount of radioactivity eliminated in urineTime frame: Day 1 pre-dose to Day 8 post-dose
  5. Cumulative amount of radioactivity eliminated in fecesTime frame: Day 1 pre-dose to Day 8 post-dose
  6. Cumulative amount of radioactivity eliminated in urine and fecesTime frame: Day 1 pre-dose to Day 8 post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Clinical

    Nottingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.